Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  New England Journal of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00006254-199901000-00021PMID 9682041
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New bisphosphonates in osteoporosis

  2005cited by this paper
• Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

  1998cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence.

  1997cited by this paper
• Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.

  1996cited by this paper
• Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis

  1996cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.

  1996cited by this paper
• Esophagitis associated with the use of alendronate.

  1996cited by this paper
• Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

  1996cited by this paper
• A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica

  1996cited by this paper
• Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.

  1995cited by this paper
• Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

  1995cited by this paper
• Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention.

  1995cited by this paper
• Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

  1995cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• The effects of analytic software and scan analysis technique on the comparison of dual X‐ray absorptiometry with dual photon absorptiometry of the hip in the elderly

  1995cited by this paper
• Decreased bone turnover in oral contraceptive users.

  1995cited by this paper
• Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids.

  1994cited by this paper
• Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

  1994cited by this paper
• Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.

  1993cited by this paper
• Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

  1993cited by this paper
• Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

  1993cited by this paper
• Predictors of fractures in early rheumatoid arthritis.

  1991cited by this paper
• Glucocorticoid-induced osteoporosis: pathogenesis and management.

  1990cited by this paper
• Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two-year prospective study.

  1989cited by this paper
• Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

  1988cited by this paper
• Testing the statistical certainty of a response to increasing doses of a drug.

  1985cited by this paper
• Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases.

  1984cited by this paper
• Steroid-induced fractures and bone loss in patients with asthma.

  1983cited by this paper
• Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.

  1979cited by this paper

• Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis

  2025influential citation
• The 2024 UK clinical guideline for the prevention and treatment of osteoporosis

  2025cites this paper
• Bone-building osteoporosis therapies and the menopause practitioner.

  2025cites this paper
• Gastroesophageal reflux disease and osteoporosis: A bidirectional Mendelian randomization study

  2025cites this paper
• Glucocorticoid-induced osteoporosis: novel concepts and clinical implications.

  2025cites this paper
• Efficacy and safety of bisphosphonates in pediatric glucocorticoid-induced osteoporosis: a meta-analysis and pharmacovigilance study

  2025cites this paper
• Therapeutic Management of Glucocorticoid-Induced Osteoporosis with a Focus on Older Adults: A Narrative Review

  2025cites this paper
• Ocular myasthenia gravis management

  2025cites this paper
• Osteoporosis in Older Men: Informing Patient Management and Improving Health-Related Outcomes

  2025cites this paper
• Drug holiday effect on osteoporosis: a narrative review of the current literature

  2024cites this paper
• Presupposti fisiopatologici e aspetti pratici della supplementazione con vitamina D in associazione con le terapie anti-riassorbitive nell’osteoporosi

  2024cites this paper
• The sequential antifracturative treatment: a meta-analysis of randomized clinical trials

  2024cites this paper
• A 70% Ethanol Neorhodomela munita Extract Attenuates RANKL-Induced Osteoclast Activation and H2O2-Induced Osteoblast Apoptosis In Vitro

  2024cites this paper
• Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis

  2024cites this paper
• Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar

  2024cites this paper
• Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss.

  2024cites this paper
• A comprehensive review on glucocorticoids induced osteoporosis: A medication caused disease.

  2024cites this paper
• Surrogate markers in assessment of bisphosphonate effectiveness in osteoporosis treatment (bone mineral density, bone turnover markers)

  2024cites this paper
• Osteoporose – Definition, Risikoerfassung, Diagnose, Prävention und Therapie (Update 2024)

  2024cites this paper
• Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in adults: Recommendations From the European Calcified Tissue Society.

  2024cites this paper
• Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

  2023cites this paper
• GLUCOCORTICOIDS IN CHRONIC DISEASE: THE GOOD, THE BAD, THE BONE.

  2023cites this paper
• Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies.

  2023cites this paper
• Bisphosphonates for osteoporosis in people with cystic fibrosis.

  2023cites this paper
• Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older

  2023cites this paper
• Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective

  2023cites this paper
• Osteoporotic vertebral compression fractures caused by Cushing’s syndrome in young women: case report and literature review

  2023cites this paper
• Extensive Expertise in Endocrinology: Advances in the Management of Glucocorticoid-Induced Osteoporosis.

  2023cites this paper
• Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?

  2023cites this paper
• Use of vitamin D with anti-osteoporotic drugs: are available clinical trials telling us the whole story?

  2023cites this paper
• Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?

  2023cites this paper
• A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis

  2023cites this paper
• Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study

  2022cites this paper
• Bone biopsy findings in patients receiving long-term bisphosphonate therapy for glucocorticoid-induced osteoporosis

  2022cites this paper
• Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

  2022cites this paper
• Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis

  2022cites this paper
• Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club

  2022cites this paper
• Induction of osteogenesis by bone-targeted Notch activation

  2022cites this paper
• Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

  2022cites this paper
• The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data

  2022cites this paper
• UK clinical guideline for the prevention and treatment of osteoporosis

  2022cites this paper
• Impact of Treat-to-Target Therapy on Bone Mineral Density Loss in Patients With Rheumatoid Arthritis: A Prospective Cohort Study

  2022cites this paper
• Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy.

  2022cites this paper
• Versatile Polymer‐Initiating Biomineralization for Tumor Blockade Therapy

  2022cites this paper
• The clinician’s guide to prevention and treatment of osteoporosis

  2022cites this paper
• Efectos adversos de la terapia con glucocorticoides

  2021cites this paper
• External cervical resorption detected via cone‐beam computed tomography in a patient with myelin oligodendrocyte glycoprotein antibody–associated disease: A case report

  2021cites this paper
• Understanding and Managing Corticosteroid-Induced Osteoporosis

  2021cites this paper
• Bisphosphonates for young patients with low BMD.

  2021cites this paper
• Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose

  2021cites this paper
• Glucocorticoid- and Transplantation-Induced Osteoporosis.

  2021cites this paper
• Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice

  2021cites this paper
• Osteopathy in mild adrenal Cushing's syndrome and Cushing disease.

  2021cites this paper
• Osteoporosis in Men: A Review of an Underestimated Bone Condition

  2021cites this paper
• Authors' reply to comments from lee and Alghamry.

  2021cites this paper
• Treatment of Glucocorticoid-Induced Osteoporosis and Risk Factors for New Vertebral Fractures in Female Patients with Autoimmune Diseases

  2021cites this paper
• Summary of the draft federal clinical guidelines for osteoporosis

  2021cites this paper
• German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis

  2021cites this paper
• Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies

  2021cites this paper
• When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

  2021cites this paper
• Treatment with an active vitamin D analogue blocks hypothalamic dysfunction-induced bone loss in mice.

  2021cites this paper
• Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study.

  2021cites this paper
• Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

  2021cites this paper
• Practical Guidance for Prevention and Management of Glucocorticoid-Induced Osteoporosis for the Allergist/Immunologist.

  2021cites this paper
• Does treatment with bisphosphonates protect against fractures in real life? The HUNT study, Norway

  2021cites this paper
• Synergistic Effect of Whitlockite Scaffolds Combined with Alendronate to Promote Bone Regeneration

  2021cites this paper
• Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)

  2021cites this paper
• Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.

  2021cites this paper
• Molecular Mechanisms and Emerging Therapeutics for Osteoporosis

  2020cites this paper
• Platelet-Rich Plasma Combined with Alendronate Reduces Pain and Inflammation in Induced Osteoarthritis in Rats by Inhibiting the Nuclear Factor-Kappa B Signaling Pathway

  2020cites this paper
• Anterior column opening structural bone grafting with posterior column compression technique for the treatment of obsolete vertebral compression fractures with severe spinal kyphosis

  2020cites this paper
• Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures

  2020cites this paper
• Glucocorticoid-induced osteoporosis: Insights for the clinician.

  2020cites this paper
• Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

  2020cites this paper
• Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

  2020cites this paper
• Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis

  2020cites this paper
• Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

  2020cites this paper
• Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B–5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark

  2020cites this paper
• Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis

  2020cites this paper
• Glucocorticoids induce osteoporosis mediated by glucocorticoid receptor-dependent and -independent pathways.

  2020cites this paper
• Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice

  2020cites this paper
• Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)

  2020cites this paper
• Thyroid Hormones, Glucocorticoids, Insulin, and Bone.

  2020cites this paper
• Treatment options for glucocorticoid-induced osteoporosis

  2020cites this paper
• ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.

  2020cites this paper
• Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study

  2020cites this paper
• Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study

  2020cites this paper
• Management of glucocorticoid-related osteoporotic vertebral fracture

  2020cites this paper
• Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials

  2020cites this paper
• Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.

  2020cites this paper
• Effect of Denosumab in Preventing Joint Destruction in Rheumatoid Arthritis With Anti-Cyclic Citrullinated Peptide Antibodies

  2020cites this paper
• Glucocorticoid-induced osteoporosis: 2019 concise clinical review

  2019influential citation
• Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial

  2019cites this paper
• Osteoporosis in Rheumatic Diseases

  2019cites this paper
• Glucocorticoid induced osteoporosis

  2019cites this paper
• DDDT_A_148654 2843..2852

  2019cites this paper
• The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper

  2019cites this paper
• Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice

  2019cites this paper
• Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis

  2019cites this paper
• Salvianolic acid B (Sal B) alleviates the decreased activity induced by prednisolone acetate on osteoblasts by up-regulation of bone formation and differentiation genes.

  2019cites this paper